Literature DB >> 9546516

Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

C Ballard, J Grace, I McKeith, C Holmes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9546516     DOI： 10.1016/s0140-6736(05)78999-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  28 in total

Review 1.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 2.  Lewy bodies and dementia.

Authors:  D Galasko
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

3.  Clomipramine induced neuroleptic malignant syndrome and pyrexia of unknown origin.

Authors:  Alison M Haddow; Dawn Harris; Martin Wilson; Hannah Logie
Journal:  BMJ       Date:  2004-12-04

4.  Recurrent spontaneous "neuroleptic malignant syndrome" in the absence of neuroleptic medication in probable dementia with Lewy bodies.

Authors:  K E Weber; R A Linker; R Lorenz; W Muellges; M Naumann; K Reiners; J Classen
Journal:  J Neurol       Date:  2005-03-14       Impact factor: 4.849

Review 5.  Clinical drug development for dementia with Lewy bodies: past and present.

Authors:  Garam Lee; Jeffrey Cummings; Boris Decourt; James B Leverenz; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2019-10-28       Impact factor: 6.206

6.  Prominent neuroleptic sensitivity in a case of early-onset Alzheimer disease due to presenilin-1 G206A mutation.

Authors:  Steven P Cercy; Martin J Sadowski; Thomas Wisniewski
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

Review 7.  Dementia with Lewy bodies: clinical features and treatment.

Authors:  S Campbell; S Stephens; C Ballard
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design.

Authors:  L Bonanni; A Cagnin; F Agosta; C Babiloni; B Borroni; M Bozzali; A C Bruni; M Filippi; D Galimberti; R Monastero; C Muscio; L Parnetti; D Perani; L Serra; V Silani; P Tiraboschi; A Padovani
Journal:  Neurol Sci       Date:  2016-09-13       Impact factor: 3.307

10.  Zotepine for behavioural and psychological symptoms in dementia: an open-label study.

Authors:  Michael K Rainer; Hermann A M Mucke; Christine Krüger-Rainer; Manfred Haushofer; Sigfried Kasper
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.